MDT-AP-1266
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- age_years
- 14
- sex
- M
- new_clusters
- C5
- umap1_2d
- 5.149719646
- umap2_2d
- 4.980986175
- umap1_3d
- 2.627862354
- umap2_3d
- -0.455642617
- umap3_3d
- -2.472141221
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- HEDGEHOG_SIGNALING+0.370
- INFLAMMATORY_RESPONSE+0.300
- IL2_STAT5_SIGNALING+0.250
- MYOGENESIS+0.250
- PANCREAS_BETA_CELLS+0.250
- ANGIOGENESIS+0.230
- ALLOGRAFT_REJECTION+0.220
- XENOBIOTIC_METABOLISM+0.210
- IL6_JAK_STAT3_SIGNALING+0.190
- KRAS_SIGNALING_DN+0.190
Top 10 suppressed
- E2F_TARGETS-0.630
- G2M_CHECKPOINT-0.590
- MYC_TARGETS_V1-0.520
- MYC_TARGETS_V2-0.460
- UNFOLDED_PROTEIN_RESPONSE-0.450
- MITOTIC_SPINDLE-0.400
- OXIDATIVE_PHOSPHORYLATION-0.340
- PROTEIN_SECRETION-0.340
- MTORC1_SIGNALING-0.330
- DNA_REPAIR-0.310
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-0746 | Med | Medulloblastoma | 0.924 |
| 2 | TCGA-55-8619-01A-11R-2403-07 | — | cohortA1 | 0.907 |
| 3 | BS_7XRN3CFX | low-grade glioma | — | 0.905 |
| 4 | MDT-AP-2130 | Med | Medulloblastoma | 0.903 |
| 5 | ERR2598336 | fetal | fetal | 0.899 |
| 6 | SRR23303748 | — | — | 0.896 |
| 7 | BS_NPQJ20KX | pilocytic astrocytoma | — | 0.890 |
| 8 | TCGA-L4-A4E6-01A-11R-A24H-07 | — | cohortA1 | 0.888 |
| 9 | BS_R244Z0WX | pilocytic astrocytoma | — | 0.888 |
| 10 | BS_GTZCFGRZ | Ganglioglioma | — | 0.887 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 27 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| HEDGEHOG_SIGNALING | 0.370 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.300 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.250 | Idelalisib | — uncovered |
| MYOGENESIS | 0.250 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.250 | Cobimetinib | — uncovered |
| ANGIOGENESIS | 0.230 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.220 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.210 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.190 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.190 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.180 | Temsirolimus | — uncovered |
| COMPLEMENT | 0.180 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.170 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.160 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.160 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.160 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.140 | Idelalisib | — uncovered |
| COAGULATION | 0.130 | Binimetinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.110 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.100 | Inavolisib | — uncovered |